The National Advertising Division (NAD) recently examined a TV ad by Bravecto, comparing its flea and tick prevention product with NexGard's. The ad suggested Bravecto's greater effectiveness, disputed by NexGard. NAD sided with NexGard, emphasizing the need for clear and conspicuous disclosures in comparative advertising.

 In a separate case, Google's ads for YouTube TV claimed a $600 cost savings over cable, leading to a dispute with a cable provider. NAD supported the cable provider, stressing the importance of clear definitions for comparable services to prevent consumer misinterpretation. 

These cases underscore the FTC's focus on addressing ambiguous and misleading comparative claims, particularly in drug product advertising—a realm already subject to FDA caution.

Support the show